Speaker Profile
M.D., CEO, RND Pharma
Biography
Dr. Mohanlal has more than 25 years of experience in the Pharmaceutical and Diagnostics industry, primarily in the therapeutic areas of Oncology, Immunology & Inflammation. He has held senior and executive positions at Novartis, Eli Lilly, BeyondSpring, Vertex and other companies). He is currently CEO at RND Pharmaceuticals, an early-stage company focusing on peripheral resistance mechanisms leading to resistance to Immune Checkpoint Inhibitor (ICI) therapy. RND has developed a Bioinformatics platform, leading to the identification of (novel) clinically validated targets and markers which correlate highly with ICI outcomes in Cancer patients.
Talk
A Novel Test for the Prediction of ICI Resistance
RND is developing a novel proprietary gene expression-based test (RND-101) for the prediction of resistance to ICI, that is >3-fold more predictive than PD-L1 (the current SoC test). RND-101 is based on a novel peripheral resistance concept of tolerogenic Dendritic Cells that fail to activate cytotoxic T-Lymphocytes, which are required for ICI effectiveness.
Clinical Dx Showcase:
RND Pharmaceuticals
RND has developed a Bioinformatics platform around peripheral resistance mechanisms, leading to the identification of (novel) clinically validated targets/markers with strong correlation with ICI outcomes in Cancer patients. This platform is the basis for developing a novel predictive test (RND-101) and novel therapeutics to overcome ICI resistance. This Bioinformatics platform will also be developed as a Spatial Biology multi-omics tool.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
